A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9?Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Administered By

Awarded By

Contributors

Start/End

  • May 13, 2021 - September 5, 2026